ACADIA Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference on March 6, 2017

SAN DIEGO—(BUSINESS WIRE)—Feb. 27, 2017—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in central nervous system disorders,today announced that it will present at the Cowen and Company 37^thAnnual Health Care Conference on Monday, March 6, 2017, at 1:20 p.m.Eastern Time in Boston.

A live webcast of ACADIA’s presentation will be accessible on thecompany’s website, www.acadia-pharm.com,under the investors section and an archived recording will be availableon the website through March 20, 2017.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA maintains a website at www.acadia-pharm.comto which we regularly post copies of our press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the progress and timing of ACADIA’sdrug discovery and development programs, and the benefits to be derivedfrom NUPLAZID^® (pimavanserin) and ACADIA’s productcandidates. These statements are only predictions based on currentinformation and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially from thoseprojected in any of such statements due to various factors, includingthe risks and uncertainties inherent in drug discovery, development,approval and commercialization, and in collaborations with others, andthe fact that past results of clinical trials may not be indicative offuture trial results. For a discussion of these and other factors,please refer to ACADIA’s annual report on Form 10-K for the year endedDecember 31, 2015 as well as ACADIA’s subsequent filings with theSecurities and Exchange Commission. You are cautioned not to place unduereliance on these forward-looking statements, which speak only as of thedate hereof. This caution is made under the safe harbor provisions ofthe Private Securities Litigation Reform Act of 1995. Allforward-looking statements are qualified in their entirety by thiscautionary statement and ACADIA undertakes no obligation to revise orupdate this press release to reflect events or circumstances after thedate hereof, except as required by law.

Source: ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, InvestorRelations
(858) 558-2871
ir@acadia-pharm.com